nodes	percent_of_prediction	percent_of_DWPC	metapath
Leflunomide—ABCG2—Sulfasalazine—Crohn's disease	0.139	1	CbGbCtD
Leflunomide—PTK2B—Signal regulatory protein (SIRP) family interactions—SKAP2—Crohn's disease	0.033	0.159	CbGpPWpGaD
Leflunomide—DHODH—skin of body—Crohn's disease	0.0121	0.155	CbGeAlD
Leflunomide—DHODH—lymphoid tissue—Crohn's disease	0.00977	0.125	CbGeAlD
Leflunomide—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—CPEB4—Crohn's disease	0.00925	0.0445	CbGpPWpGaD
Leflunomide—PTK2B—smooth muscle tissue—Crohn's disease	0.00774	0.0994	CbGeAlD
Leflunomide—AHR—smooth muscle tissue—Crohn's disease	0.00637	0.0817	CbGeAlD
Leflunomide—PTK2B—lymphoid tissue—Crohn's disease	0.00619	0.0795	CbGeAlD
Leflunomide—AHR—Aryl Hydrocarbon Receptor Pathway—IL12B—Crohn's disease	0.00614	0.0296	CbGpPWpGaD
Leflunomide—PTK2B—digestive system—Crohn's disease	0.00611	0.0785	CbGeAlD
Leflunomide—AHR—mammalian vulva—Crohn's disease	0.00573	0.0736	CbGeAlD
Leflunomide—DHODH—lymph node—Crohn's disease	0.00551	0.0708	CbGeAlD
Leflunomide—PTK2B—Coregulation of Androgen receptor activity—ZMIZ1—Crohn's disease	0.00526	0.0253	CbGpPWpGaD
Leflunomide—PTK2B—Cell-Cell communication—SKAP2—Crohn's disease	0.00524	0.0252	CbGpPWpGaD
Leflunomide—AHR—digestive system—Crohn's disease	0.00503	0.0645	CbGeAlD
Leflunomide—AHR—Circadian rythm related genes—CREM—Crohn's disease	0.00467	0.0225	CbGpPWpGaD
Leflunomide—AHR—Integrated Breast Cancer Pathway—ZMIZ1—Crohn's disease	0.00464	0.0223	CbGpPWpGaD
Leflunomide—PTK2B—BDNF signaling pathway—KSR1—Crohn's disease	0.00441	0.0212	CbGpPWpGaD
Leflunomide—PTK2B—Alpha4 beta1 integrin signaling events—ITGA4—Crohn's disease	0.0042	0.0202	CbGpPWpGaD
Leflunomide—Niflumic Acid—PTGS2—Crohn's disease	0.00373	1	CrCbGaD
Leflunomide—PTK2B—IL-7 Signaling Pathway—IL2RA—Crohn's disease	0.00358	0.0172	CbGpPWpGaD
Leflunomide—PTK2B—lymph node—Crohn's disease	0.00349	0.0448	CbGeAlD
Leflunomide—PTK2B—Interleukin-2 signaling—IL3—Crohn's disease	0.00308	0.0148	CbGpPWpGaD
Leflunomide—PTK2B—Apoptosis-related network due to altered Notch3 in ovarian cancer—RIPK2—Crohn's disease	0.00287	0.0138	CbGpPWpGaD
Leflunomide—AHR—lymph node—Crohn's disease	0.00287	0.0369	CbGeAlD
Leflunomide—PTK2B—Signaling events mediated by VEGFR1 and VEGFR2—PTPN2—Crohn's disease	0.0028	0.0135	CbGpPWpGaD
Leflunomide—AHR—Aryl Hydrocarbon Receptor Pathway—IFNG—Crohn's disease	0.00264	0.0127	CbGpPWpGaD
Leflunomide—AHR—Aryl Hydrocarbon Receptor—PTGS2—Crohn's disease	0.00253	0.0122	CbGpPWpGaD
Leflunomide—PTK2B—IL2-mediated signaling events—SOCS1—Crohn's disease	0.00242	0.0116	CbGpPWpGaD
Leflunomide—Ecchymosis—Mesalazine—Crohn's disease	0.00238	0.00417	CcSEcCtD
Leflunomide—Bladder pain—Mesalazine—Crohn's disease	0.00238	0.00417	CcSEcCtD
Leflunomide—Mouth ulceration—Mesalazine—Crohn's disease	0.00238	0.00417	CcSEcCtD
Leflunomide—PTK2B—IL-2 Signaling Pathway—IL2RA—Crohn's disease	0.00236	0.0114	CbGpPWpGaD
Leflunomide—AHR—Aryl Hydrocarbon Receptor Pathway—IL1B—Crohn's disease	0.00236	0.0113	CbGpPWpGaD
Leflunomide—Hepatic failure—Azathioprine—Crohn's disease	0.00234	0.00409	CcSEcCtD
Leflunomide—PTK2B—Signaling by Interleukins—NOD1—Crohn's disease	0.00233	0.0112	CbGpPWpGaD
Leflunomide—Lymphadenopathy—Mesalazine—Crohn's disease	0.00224	0.00393	CcSEcCtD
Leflunomide—ABCG2—mammalian vulva—Crohn's disease	0.00222	0.0285	CbGeAlD
Leflunomide—Immune system disorder—Mercaptopurine—Crohn's disease	0.0022	0.00386	CcSEcCtD
Leflunomide—AHR—Adipogenesis—SOCS1—Crohn's disease	0.00218	0.0105	CbGpPWpGaD
Leflunomide—PTK2B—Interleukin-2 signaling—IL2RA—Crohn's disease	0.00216	0.0104	CbGpPWpGaD
Leflunomide—Gastroenteritis—Mesalazine—Crohn's disease	0.00216	0.00378	CcSEcCtD
Leflunomide—Alopecia—Mercaptopurine—Crohn's disease	0.00216	0.00378	CcSEcCtD
Leflunomide—Hepatic failure—Mesalazine—Crohn's disease	0.00213	0.00373	CcSEcCtD
Leflunomide—Eczema—Mesalazine—Crohn's disease	0.00213	0.00373	CcSEcCtD
Leflunomide—Malnutrition—Mercaptopurine—Crohn's disease	0.00212	0.00372	CcSEcCtD
Leflunomide—PTK2B—TCR Signaling Pathway—IL17A—Crohn's disease	0.00212	0.0102	CbGpPWpGaD
Leflunomide—AHR—Integrated Breast Cancer Pathway—TAB1—Crohn's disease	0.00209	0.0101	CbGpPWpGaD
Leflunomide—Arthritis—Mesalazine—Crohn's disease	0.00197	0.00345	CcSEcCtD
Leflunomide—Anaemia—Mercaptopurine—Crohn's disease	0.00196	0.00344	CcSEcCtD
Leflunomide—PTK2B—IL2-mediated signaling events—IL2RA—Crohn's disease	0.00193	0.0093	CbGpPWpGaD
Leflunomide—Osteoarthritis—Mesalazine—Crohn's disease	0.00191	0.00335	CcSEcCtD
Leflunomide—PTK2B—Signaling by Interleukins—RBX1—Crohn's disease	0.00191	0.0092	CbGpPWpGaD
Leflunomide—Leukopenia—Mercaptopurine—Crohn's disease	0.0019	0.00333	CcSEcCtD
Leflunomide—Toxic epidermal necrolysis—Azathioprine—Crohn's disease	0.00189	0.00331	CcSEcCtD
Leflunomide—Migraine—Mesalazine—Crohn's disease	0.00188	0.0033	CcSEcCtD
Leflunomide—AHR—Adipogenesis—SMAD3—Crohn's disease	0.00188	0.00906	CbGpPWpGaD
Leflunomide—PTK2B—TCR Signaling Pathway—RIPK2—Crohn's disease	0.00188	0.00905	CbGpPWpGaD
Leflunomide—CYP1A2—digestive system—Crohn's disease	0.00188	0.0241	CbGeAlD
Leflunomide—Neuritis—Prednisone—Crohn's disease	0.00187	0.00327	CcSEcCtD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—IFNGR2—Crohn's disease	0.00183	0.00879	CbGpPWpGaD
Leflunomide—Arthralgia—Mercaptopurine—Crohn's disease	0.00181	0.00317	CcSEcCtD
Leflunomide—Unspecified disorder of skin and subcutaneous tissue—Mercaptopurine—Crohn's disease	0.0018	0.00314	CcSEcCtD
Leflunomide—CYP2C9—digestive system—Crohn's disease	0.00178	0.0229	CbGeAlD
Leflunomide—Pancreatitis—Azathioprine—Crohn's disease	0.00178	0.00312	CcSEcCtD
Leflunomide—Liver function test abnormal—Mesalazine—Crohn's disease	0.00177	0.00309	CcSEcCtD
Leflunomide—PTK2B—IL-7 Signaling Pathway—STAT3—Crohn's disease	0.00177	0.0085	CbGpPWpGaD
Leflunomide—Abscess—Prednisone—Crohn's disease	0.00176	0.00309	CcSEcCtD
Leflunomide—Dry skin—Mesalazine—Crohn's disease	0.00175	0.00307	CcSEcCtD
Leflunomide—Breast disorder—Mesalazine—Crohn's disease	0.00173	0.00303	CcSEcCtD
Leflunomide—Pancytopenia—Azathioprine—Crohn's disease	0.00172	0.00302	CcSEcCtD
Leflunomide—Cramp muscle—Mesalazine—Crohn's disease	0.00172	0.00302	CcSEcCtD
Leflunomide—AHR—Aryl Hydrocarbon Receptor Pathway—TNF—Crohn's disease	0.00171	0.00823	CbGpPWpGaD
Leflunomide—AHR—Aryl Hydrocarbon Receptor—TNF—Crohn's disease	0.00171	0.00823	CbGpPWpGaD
Leflunomide—Thrombocytopenia—Mercaptopurine—Crohn's disease	0.0017	0.00297	CcSEcCtD
Leflunomide—Gastritis—Mesalazine—Crohn's disease	0.00169	0.00297	CcSEcCtD
Leflunomide—Skin disorder—Mercaptopurine—Crohn's disease	0.00168	0.00295	CcSEcCtD
Leflunomide—Endocrine disorder—Prednisone—Crohn's disease	0.00168	0.00295	CcSEcCtD
Leflunomide—Acne—Prednisone—Crohn's disease	0.00166	0.0029	CcSEcCtD
Leflunomide—Asthma—Mesalazine—Crohn's disease	0.00165	0.0029	CcSEcCtD
Leflunomide—Influenza—Mesalazine—Crohn's disease	0.00165	0.0029	CcSEcCtD
Leflunomide—Anorexia—Mercaptopurine—Crohn's disease	0.00165	0.00289	CcSEcCtD
Leflunomide—Eosinophilia—Mesalazine—Crohn's disease	0.00164	0.00287	CcSEcCtD
Leflunomide—Pneumonia—Azathioprine—Crohn's disease	0.00163	0.00285	CcSEcCtD
Leflunomide—PTK2B—Signaling by Interleukins—RIPK2—Crohn's disease	0.00163	0.00782	CbGpPWpGaD
Leflunomide—Pancreatitis—Mesalazine—Crohn's disease	0.00162	0.00284	CcSEcCtD
Leflunomide—Infestation NOS—Azathioprine—Crohn's disease	0.00162	0.00284	CcSEcCtD
Leflunomide—Infestation—Azathioprine—Crohn's disease	0.00162	0.00284	CcSEcCtD
Leflunomide—Angina pectoris—Mesalazine—Crohn's disease	0.00161	0.00282	CcSEcCtD
Leflunomide—Stevens-Johnson syndrome—Azathioprine—Crohn's disease	0.00161	0.00281	CcSEcCtD
Leflunomide—Contusion—Prednisone—Crohn's disease	0.0016	0.0028	CcSEcCtD
Leflunomide—Bronchitis—Mesalazine—Crohn's disease	0.00159	0.00279	CcSEcCtD
Leflunomide—PTK2B—Signaling by Interleukins—IL3—Crohn's disease	0.00159	0.00763	CbGpPWpGaD
Leflunomide—Musculoskeletal discomfort—Mercaptopurine—Crohn's disease	0.00158	0.00277	CcSEcCtD
Leflunomide—Pancytopenia—Mesalazine—Crohn's disease	0.00157	0.00275	CcSEcCtD
Leflunomide—Neutropenia—Mesalazine—Crohn's disease	0.00155	0.00271	CcSEcCtD
Leflunomide—Dysuria—Mesalazine—Crohn's disease	0.00155	0.00271	CcSEcCtD
Leflunomide—Upper respiratory tract infection—Mesalazine—Crohn's disease	0.00154	0.00269	CcSEcCtD
Leflunomide—Arthropathy—Prednisone—Crohn's disease	0.00153	0.00269	CcSEcCtD
Leflunomide—Hepatobiliary disease—Azathioprine—Crohn's disease	0.00153	0.00268	CcSEcCtD
Leflunomide—Pollakiuria—Mesalazine—Crohn's disease	0.00153	0.00268	CcSEcCtD
Leflunomide—PTK2B—Interleukin-2 signaling—TYK2—Crohn's disease	0.00152	0.00732	CbGpPWpGaD
Leflunomide—Agranulocytosis—Azathioprine—Crohn's disease	0.00151	0.00265	CcSEcCtD
Leflunomide—Decreased appetite—Mercaptopurine—Crohn's disease	0.00151	0.00264	CcSEcCtD
Leflunomide—PTK2B—Signaling by Interleukins—TAB1—Crohn's disease	0.0015	0.00722	CbGpPWpGaD
Leflunomide—Weight decreased—Mesalazine—Crohn's disease	0.0015	0.00262	CcSEcCtD
Leflunomide—Gastrointestinal disorder—Mercaptopurine—Crohn's disease	0.0015	0.00262	CcSEcCtD
Leflunomide—Pneumonia—Mesalazine—Crohn's disease	0.00148	0.0026	CcSEcCtD
Leflunomide—Infestation NOS—Mesalazine—Crohn's disease	0.00147	0.00258	CcSEcCtD
Leflunomide—Infestation—Mesalazine—Crohn's disease	0.00147	0.00258	CcSEcCtD
Leflunomide—Ulcer—Prednisone—Crohn's disease	0.00147	0.00258	CcSEcCtD
Leflunomide—PTK2B—Signaling by Interleukins—NOD2—Crohn's disease	0.00147	0.00709	CbGpPWpGaD
Leflunomide—Cataract—Prednisone—Crohn's disease	0.00147	0.00257	CcSEcCtD
Leflunomide—Stevens-Johnson syndrome—Mesalazine—Crohn's disease	0.00146	0.00256	CcSEcCtD
Leflunomide—Haemoglobin—Azathioprine—Crohn's disease	0.00146	0.00256	CcSEcCtD
Leflunomide—Haemorrhage—Azathioprine—Crohn's disease	0.00145	0.00255	CcSEcCtD
Leflunomide—PTK2B—Interleukin-2 signaling—JAK2—Crohn's disease	0.00145	0.00699	CbGpPWpGaD
Leflunomide—Renal failure—Mesalazine—Crohn's disease	0.00145	0.00254	CcSEcCtD
Leflunomide—Neuropathy peripheral—Mesalazine—Crohn's disease	0.00145	0.00253	CcSEcCtD
Leflunomide—Jaundice—Mesalazine—Crohn's disease	0.00144	0.00252	CcSEcCtD
Leflunomide—Stomatitis—Mesalazine—Crohn's disease	0.00144	0.00252	CcSEcCtD
Leflunomide—Conjunctivitis—Mesalazine—Crohn's disease	0.00143	0.00251	CcSEcCtD
Leflunomide—Urinary tract infection—Mesalazine—Crohn's disease	0.00143	0.00251	CcSEcCtD
Leflunomide—Vasculitis—Prednisone—Crohn's disease	0.00143	0.0025	CcSEcCtD
Leflunomide—DHODH—Metabolism—PLA2G4F—Crohn's disease	0.00143	0.00686	CbGpPWpGaD
Leflunomide—Haematuria—Mesalazine—Crohn's disease	0.00141	0.00246	CcSEcCtD
Leflunomide—Hepatobiliary disease—Mesalazine—Crohn's disease	0.00139	0.00244	CcSEcCtD
Leflunomide—Epistaxis—Mesalazine—Crohn's disease	0.00139	0.00244	CcSEcCtD
Leflunomide—Sinusitis—Mesalazine—Crohn's disease	0.00138	0.00242	CcSEcCtD
Leflunomide—PTK2B—Signaling of Hepatocyte Growth Factor Receptor—STAT3—Crohn's disease	0.00138	0.00664	CbGpPWpGaD
Leflunomide—Agranulocytosis—Mesalazine—Crohn's disease	0.00138	0.00241	CcSEcCtD
Leflunomide—Erythema multiforme—Azathioprine—Crohn's disease	0.00137	0.00241	CcSEcCtD
Leflunomide—Body temperature increased—Mercaptopurine—Crohn's disease	0.00137	0.0024	CcSEcCtD
Leflunomide—Haemoglobin—Mesalazine—Crohn's disease	0.00133	0.00233	CcSEcCtD
Leflunomide—Rhinitis—Mesalazine—Crohn's disease	0.00133	0.00232	CcSEcCtD
Leflunomide—Haemorrhage—Mesalazine—Crohn's disease	0.00132	0.00232	CcSEcCtD
Leflunomide—Hepatitis—Mesalazine—Crohn's disease	0.00132	0.00232	CcSEcCtD
Leflunomide—Pharyngitis—Mesalazine—Crohn's disease	0.00131	0.0023	CcSEcCtD
Leflunomide—Immune system disorder—Azathioprine—Crohn's disease	0.00131	0.0023	CcSEcCtD
Leflunomide—Mediastinal disorder—Azathioprine—Crohn's disease	0.00131	0.00229	CcSEcCtD
Leflunomide—Urinary tract disorder—Mesalazine—Crohn's disease	0.00131	0.00229	CcSEcCtD
Leflunomide—Oedema peripheral—Mesalazine—Crohn's disease	0.0013	0.00228	CcSEcCtD
Leflunomide—Chills—Azathioprine—Crohn's disease	0.0013	0.00228	CcSEcCtD
Leflunomide—Connective tissue disorder—Mesalazine—Crohn's disease	0.0013	0.00228	CcSEcCtD
Leflunomide—Arrhythmia—Azathioprine—Crohn's disease	0.0013	0.00227	CcSEcCtD
Leflunomide—Urethral disorder—Mesalazine—Crohn's disease	0.0013	0.00227	CcSEcCtD
Leflunomide—Alopecia—Azathioprine—Crohn's disease	0.00128	0.00225	CcSEcCtD
Leflunomide—Hypersensitivity—Mercaptopurine—Crohn's disease	0.00128	0.00224	CcSEcCtD
Leflunomide—PTK2B—IL2-mediated signaling events—IFNG—Crohn's disease	0.00128	0.00614	CbGpPWpGaD
Leflunomide—Oesophagitis—Prednisone—Crohn's disease	0.00127	0.00223	CcSEcCtD
Leflunomide—Ecchymosis—Prednisone—Crohn's disease	0.00126	0.00221	CcSEcCtD
Leflunomide—Erythema multiforme—Mesalazine—Crohn's disease	0.00125	0.00219	CcSEcCtD
Leflunomide—PTK2B—Signaling by Interleukins—IL18—Crohn's disease	0.00125	0.00602	CbGpPWpGaD
Leflunomide—Eye disorder—Mesalazine—Crohn's disease	0.00124	0.00217	CcSEcCtD
Leflunomide—Cardiac disorder—Mesalazine—Crohn's disease	0.00123	0.00215	CcSEcCtD
Leflunomide—DHODH—Metabolism—MTMR3—Crohn's disease	0.00121	0.00583	CbGpPWpGaD
Leflunomide—Sepsis—Prednisone—Crohn's disease	0.00121	0.00212	CcSEcCtD
Leflunomide—Immune system disorder—Mesalazine—Crohn's disease	0.0012	0.00209	CcSEcCtD
Leflunomide—Mediastinal disorder—Mesalazine—Crohn's disease	0.00119	0.00209	CcSEcCtD
Leflunomide—Chills—Mesalazine—Crohn's disease	0.00119	0.00208	CcSEcCtD
Leflunomide—Diarrhoea—Mercaptopurine—Crohn's disease	0.00119	0.00208	CcSEcCtD
Leflunomide—PTK2B—Oncostatin M Signaling Pathway—TYK2—Crohn's disease	0.00117	0.00565	CbGpPWpGaD
Leflunomide—Ill-defined disorder—Azathioprine—Crohn's disease	0.00117	0.00206	CcSEcCtD
Leflunomide—Alopecia—Mesalazine—Crohn's disease	0.00117	0.00205	CcSEcCtD
Leflunomide—Anaemia—Azathioprine—Crohn's disease	0.00117	0.00205	CcSEcCtD
Leflunomide—PTK2B—IL-2 Signaling Pathway—STAT3—Crohn's disease	0.00117	0.00561	CbGpPWpGaD
Leflunomide—Diabetes mellitus—Prednisone—Crohn's disease	0.00116	0.00204	CcSEcCtD
Leflunomide—Mental disorder—Mesalazine—Crohn's disease	0.00116	0.00203	CcSEcCtD
Leflunomide—PTK2B—Endothelins—JAK2—Crohn's disease	0.00115	0.00553	CbGpPWpGaD
Leflunomide—Malaise—Azathioprine—Crohn's disease	0.00114	0.002	CcSEcCtD
Leflunomide—Flatulence—Mesalazine—Crohn's disease	0.00114	0.00199	CcSEcCtD
Leflunomide—CYP2C9—Arachidonic acid metabolism—GPX4—Crohn's disease	0.00114	0.00546	CbGpPWpGaD
Leflunomide—Leukopenia—Azathioprine—Crohn's disease	0.00113	0.00198	CcSEcCtD
Leflunomide—Dysgeusia—Mesalazine—Crohn's disease	0.00113	0.00198	CcSEcCtD
Leflunomide—PTK2B—Oncostatin M Signaling Pathway—JAK2—Crohn's disease	0.00112	0.00539	CbGpPWpGaD
Leflunomide—Back pain—Mesalazine—Crohn's disease	0.00111	0.00195	CcSEcCtD
Leflunomide—ABCG2—lymph node—Crohn's disease	0.00111	0.0143	CbGeAlD
Leflunomide—PTK2B—Signaling by Interleukins—IL2RA—Crohn's disease	0.00111	0.00534	CbGpPWpGaD
Leflunomide—Muscle spasms—Mesalazine—Crohn's disease	0.00111	0.00194	CcSEcCtD
Leflunomide—Vomiting—Mercaptopurine—Crohn's disease	0.0011	0.00193	CcSEcCtD
Leflunomide—Rash—Mercaptopurine—Crohn's disease	0.00109	0.00191	CcSEcCtD
Leflunomide—Dermatitis—Mercaptopurine—Crohn's disease	0.00109	0.00191	CcSEcCtD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—NOD1—Crohn's disease	0.00109	0.00523	CbGpPWpGaD
Leflunomide—Vision blurred—Mesalazine—Crohn's disease	0.00109	0.0019	CcSEcCtD
Leflunomide—Arthralgia—Azathioprine—Crohn's disease	0.00108	0.00189	CcSEcCtD
Leflunomide—Myalgia—Azathioprine—Crohn's disease	0.00108	0.00189	CcSEcCtD
Leflunomide—Unspecified disorder of skin and subcutaneous tissue—Azathioprine—Crohn's disease	0.00107	0.00187	CcSEcCtD
Leflunomide—Ill-defined disorder—Mesalazine—Crohn's disease	0.00107	0.00187	CcSEcCtD
Leflunomide—Anaemia—Mesalazine—Crohn's disease	0.00107	0.00187	CcSEcCtD
Leflunomide—Discomfort—Azathioprine—Crohn's disease	0.00106	0.00186	CcSEcCtD
Leflunomide—Angioedema—Mesalazine—Crohn's disease	0.00105	0.00184	CcSEcCtD
Leflunomide—Malaise—Mesalazine—Crohn's disease	0.00104	0.00182	CcSEcCtD
Leflunomide—Vertigo—Mesalazine—Crohn's disease	0.00104	0.00181	CcSEcCtD
Leflunomide—PTK2B—LPA receptor mediated events—CXCL8—Crohn's disease	0.00104	0.00498	CbGpPWpGaD
Leflunomide—Leukopenia—Mesalazine—Crohn's disease	0.00103	0.00181	CcSEcCtD
Leflunomide—Nausea—Mercaptopurine—Crohn's disease	0.00103	0.0018	CcSEcCtD
Leflunomide—Infection—Azathioprine—Crohn's disease	0.00103	0.0018	CcSEcCtD
Leflunomide—Palpitations—Mesalazine—Crohn's disease	0.00102	0.00178	CcSEcCtD
Leflunomide—Osteoarthritis—Prednisone—Crohn's disease	0.00101	0.00177	CcSEcCtD
Leflunomide—Thrombocytopenia—Azathioprine—Crohn's disease	0.00101	0.00177	CcSEcCtD
Leflunomide—Cough—Mesalazine—Crohn's disease	0.00101	0.00176	CcSEcCtD
Leflunomide—Skin disorder—Azathioprine—Crohn's disease	0.001	0.00176	CcSEcCtD
Leflunomide—Hypertension—Mesalazine—Crohn's disease	0.000995	0.00174	CcSEcCtD
Leflunomide—Chest pain—Mesalazine—Crohn's disease	0.000981	0.00172	CcSEcCtD
Leflunomide—Myalgia—Mesalazine—Crohn's disease	0.000981	0.00172	CcSEcCtD
Leflunomide—Arthralgia—Mesalazine—Crohn's disease	0.000981	0.00172	CcSEcCtD
Leflunomide—Anxiety—Mesalazine—Crohn's disease	0.000978	0.00171	CcSEcCtD
Leflunomide—Unspecified disorder of skin and subcutaneous tissue—Mesalazine—Crohn's disease	0.000975	0.00171	CcSEcCtD
Leflunomide—CYP1A2—Arachidonic acid metabolism—GPX4—Crohn's disease	0.00097	0.00467	CbGpPWpGaD
Leflunomide—Discomfort—Mesalazine—Crohn's disease	0.00097	0.0017	CcSEcCtD
Leflunomide—Hypotension—Azathioprine—Crohn's disease	0.000965	0.00169	CcSEcCtD
Leflunomide—Dry mouth—Mesalazine—Crohn's disease	0.00096	0.00168	CcSEcCtD
Leflunomide—PTK2B—FGF signaling pathway—STAT3—Crohn's disease	0.000954	0.00459	CbGpPWpGaD
Leflunomide—PTK2B—IL2-mediated signaling events—STAT3—Crohn's disease	0.000954	0.00459	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—FADS1—Crohn's disease	0.000945	0.00454	CbGpPWpGaD
Leflunomide—Musculoskeletal discomfort—Azathioprine—Crohn's disease	0.000941	0.00165	CcSEcCtD
Leflunomide—Anaphylactic shock—Mesalazine—Crohn's disease	0.000941	0.00165	CcSEcCtD
Leflunomide—Infection—Mesalazine—Crohn's disease	0.000935	0.00164	CcSEcCtD
Leflunomide—Dry skin—Prednisone—Crohn's disease	0.000928	0.00163	CcSEcCtD
Leflunomide—PTK2B—Immune System—ERAP2—Crohn's disease	0.000926	0.00445	CbGpPWpGaD
Leflunomide—Nervous system disorder—Mesalazine—Crohn's disease	0.000923	0.00162	CcSEcCtD
Leflunomide—Hypokalaemia—Prednisone—Crohn's disease	0.000922	0.00161	CcSEcCtD
Leflunomide—Thrombocytopenia—Mesalazine—Crohn's disease	0.000921	0.00161	CcSEcCtD
Leflunomide—Tachycardia—Mesalazine—Crohn's disease	0.000918	0.00161	CcSEcCtD
Leflunomide—Skin disorder—Mesalazine—Crohn's disease	0.000914	0.0016	CcSEcCtD
Leflunomide—PTK2B—CXCR4-mediated signaling events—JAK2—Crohn's disease	0.000913	0.00439	CbGpPWpGaD
Leflunomide—Hyperhidrosis—Mesalazine—Crohn's disease	0.000909	0.00159	CcSEcCtD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—PTPN2—Crohn's disease	0.000902	0.00434	CbGpPWpGaD
Leflunomide—Anorexia—Mesalazine—Crohn's disease	0.000897	0.00157	CcSEcCtD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—RBX1—Crohn's disease	0.000892	0.00429	CbGpPWpGaD
Leflunomide—Gastrointestinal disorder—Azathioprine—Crohn's disease	0.000892	0.00156	CcSEcCtD
Leflunomide—DHODH—Metabolism—GPX4—Crohn's disease	0.000885	0.00426	CbGpPWpGaD
Leflunomide—Hypotension—Mesalazine—Crohn's disease	0.000879	0.00154	CcSEcCtD
Leflunomide—PTK2B—CXCR4-mediated signaling events—CD4—Crohn's disease	0.000865	0.00416	CbGpPWpGaD
Leflunomide—AHR—Adipogenesis—STAT3—Crohn's disease	0.000861	0.00414	CbGpPWpGaD
Leflunomide—Pancreatitis—Prednisone—Crohn's disease	0.000858	0.0015	CcSEcCtD
Leflunomide—Musculoskeletal discomfort—Mesalazine—Crohn's disease	0.000857	0.0015	CcSEcCtD
Leflunomide—DHODH—Metabolism—GCKR—Crohn's disease	0.000854	0.00411	CbGpPWpGaD
Leflunomide—Sweating increased—Prednisone—Crohn's disease	0.000853	0.00149	CcSEcCtD
Leflunomide—Feeling abnormal—Azathioprine—Crohn's disease	0.000851	0.00149	CcSEcCtD
Leflunomide—Insomnia—Mesalazine—Crohn's disease	0.000851	0.00149	CcSEcCtD
Leflunomide—Paraesthesia—Mesalazine—Crohn's disease	0.000845	0.00148	CcSEcCtD
Leflunomide—Gastrointestinal pain—Azathioprine—Crohn's disease	0.000844	0.00148	CcSEcCtD
Leflunomide—Dyspnoea—Mesalazine—Crohn's disease	0.000839	0.00147	CcSEcCtD
Leflunomide—PTK2B—Apoptosis-related network due to altered Notch3 in ovarian cancer—TNF—Crohn's disease	0.000838	0.00403	CbGpPWpGaD
Leflunomide—Dyspepsia—Mesalazine—Crohn's disease	0.000828	0.00145	CcSEcCtD
Leflunomide—ABCG2—HIF-1-alpha transcription factor network—SMAD3—Crohn's disease	0.000827	0.00398	CbGpPWpGaD
Leflunomide—PTK2B—Oncostatin M Signaling Pathway—STAT3—Crohn's disease	0.000822	0.00396	CbGpPWpGaD
Leflunomide—PTK2B—TCR Signaling Pathway—CD4—Crohn's disease	0.000819	0.00394	CbGpPWpGaD
Leflunomide—Neutropenia—Prednisone—Crohn's disease	0.000818	0.00143	CcSEcCtD
Leflunomide—Decreased appetite—Mesalazine—Crohn's disease	0.000818	0.00143	CcSEcCtD
Leflunomide—Body temperature increased—Azathioprine—Crohn's disease	0.000816	0.00143	CcSEcCtD
Leflunomide—Abdominal pain—Azathioprine—Crohn's disease	0.000816	0.00143	CcSEcCtD
Leflunomide—Gastrointestinal disorder—Mesalazine—Crohn's disease	0.000812	0.00142	CcSEcCtD
Leflunomide—Fatigue—Mesalazine—Crohn's disease	0.000811	0.00142	CcSEcCtD
Leflunomide—Pain—Mesalazine—Crohn's disease	0.000804	0.00141	CcSEcCtD
Leflunomide—Constipation—Mesalazine—Crohn's disease	0.000804	0.00141	CcSEcCtD
Leflunomide—Weight decreased—Prednisone—Crohn's disease	0.000792	0.00139	CcSEcCtD
Leflunomide—Hyperglycaemia—Prednisone—Crohn's disease	0.00079	0.00138	CcSEcCtD
Leflunomide—PTK2B—VEGFA-VEGFR2 Pathway—TYK2—Crohn's disease	0.000788	0.00379	CbGpPWpGaD
Leflunomide—PTK2B—Signaling by Interleukins—TYK2—Crohn's disease	0.000782	0.00376	CbGpPWpGaD
Leflunomide—Feeling abnormal—Mesalazine—Crohn's disease	0.000775	0.00136	CcSEcCtD
Leflunomide—Gastrointestinal pain—Mesalazine—Crohn's disease	0.000769	0.00135	CcSEcCtD
Leflunomide—Neuropathy peripheral—Prednisone—Crohn's disease	0.000765	0.00134	CcSEcCtD
Leflunomide—Hypersensitivity—Azathioprine—Crohn's disease	0.000761	0.00133	CcSEcCtD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—RIPK2—Crohn's disease	0.000759	0.00365	CbGpPWpGaD
Leflunomide—PTK2B—TCR Signaling Pathway—IL1B—Crohn's disease	0.000756	0.00364	CbGpPWpGaD
Leflunomide—PTK2B—VEGFA-VEGFR2 Pathway—JAK2—Crohn's disease	0.000752	0.00362	CbGpPWpGaD
Leflunomide—Urticaria—Mesalazine—Crohn's disease	0.000747	0.00131	CcSEcCtD
Leflunomide—PTK2B—Signaling by Interleukins—JAK2—Crohn's disease	0.000746	0.00359	CbGpPWpGaD
Leflunomide—AHR—Adipogenesis—TNF—Crohn's disease	0.000745	0.00358	CbGpPWpGaD
Leflunomide—PTK2B—Interleukin-2 signaling—IL6—Crohn's disease	0.000745	0.00358	CbGpPWpGaD
Leflunomide—PTK2B—Signaling by VEGF—TYK2—Crohn's disease	0.000744	0.00358	CbGpPWpGaD
Leflunomide—Body temperature increased—Mesalazine—Crohn's disease	0.000744	0.0013	CcSEcCtD
Leflunomide—Abdominal pain—Mesalazine—Crohn's disease	0.000744	0.0013	CcSEcCtD
Leflunomide—PTK2B—Immune System—MADCAM1—Crohn's disease	0.00074	0.00356	CbGpPWpGaD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—IL3—Crohn's disease	0.00074	0.00356	CbGpPWpGaD
Leflunomide—PTK2B—Signaling by VEGF—JAK2—Crohn's disease	0.00071	0.00341	CbGpPWpGaD
Leflunomide—Diarrhoea—Azathioprine—Crohn's disease	0.000707	0.00124	CcSEcCtD
Leflunomide—Haemoglobin—Prednisone—Crohn's disease	0.000704	0.00123	CcSEcCtD
Leflunomide—Haemorrhage—Prednisone—Crohn's disease	0.000701	0.00123	CcSEcCtD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—TAB1—Crohn's disease	0.0007	0.00337	CbGpPWpGaD
Leflunomide—Hypersensitivity—Mesalazine—Crohn's disease	0.000693	0.00121	CcSEcCtD
Leflunomide—Connective tissue disorder—Prednisone—Crohn's disease	0.000688	0.00121	CcSEcCtD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—NOD2—Crohn's disease	0.000688	0.00331	CbGpPWpGaD
Leflunomide—Dizziness—Azathioprine—Crohn's disease	0.000683	0.0012	CcSEcCtD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12B—Crohn's disease	0.000677	0.00326	CbGpPWpGaD
Leflunomide—Asthenia—Mesalazine—Crohn's disease	0.000675	0.00118	CcSEcCtD
Leflunomide—PTK2B—CXCR4-mediated signaling events—STAT3—Crohn's disease	0.00067	0.00322	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—ICOSLG—Crohn's disease	0.000669	0.00322	CbGpPWpGaD
Leflunomide—Pruritus—Mesalazine—Crohn's disease	0.000666	0.00117	CcSEcCtD
Leflunomide—Vomiting—Azathioprine—Crohn's disease	0.000657	0.00115	CcSEcCtD
Leflunomide—Eye disorder—Prednisone—Crohn's disease	0.000655	0.00115	CcSEcCtD
Leflunomide—PTK2B—Signaling by Interleukins—IL1B—Crohn's disease	0.000654	0.00314	CbGpPWpGaD
Leflunomide—Rash—Azathioprine—Crohn's disease	0.000651	0.00114	CcSEcCtD
Leflunomide—Dermatitis—Azathioprine—Crohn's disease	0.000651	0.00114	CcSEcCtD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—SOCS1—Crohn's disease	0.000648	0.00312	CbGpPWpGaD
Leflunomide—Headache—Azathioprine—Crohn's disease	0.000647	0.00113	CcSEcCtD
Leflunomide—Diarrhoea—Mesalazine—Crohn's disease	0.000644	0.00113	CcSEcCtD
Leflunomide—Immune system disorder—Prednisone—Crohn's disease	0.000633	0.00111	CcSEcCtD
Leflunomide—Arrhythmia—Prednisone—Crohn's disease	0.000626	0.0011	CcSEcCtD
Leflunomide—Dizziness—Mesalazine—Crohn's disease	0.000622	0.00109	CcSEcCtD
Leflunomide—Alopecia—Prednisone—Crohn's disease	0.000619	0.00108	CcSEcCtD
Leflunomide—Mental disorder—Prednisone—Crohn's disease	0.000614	0.00107	CcSEcCtD
Leflunomide—Nausea—Azathioprine—Crohn's disease	0.000613	0.00107	CcSEcCtD
Leflunomide—Malnutrition—Prednisone—Crohn's disease	0.00061	0.00107	CcSEcCtD
Leflunomide—AHR—Adipogenesis—IL6—Crohn's disease	0.000601	0.00289	CbGpPWpGaD
Leflunomide—Vomiting—Mesalazine—Crohn's disease	0.000598	0.00105	CcSEcCtD
Leflunomide—CYP1A2—Estrogen Receptor Pathway—STAT3—Crohn's disease	0.000598	0.00288	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—DEFA5—Crohn's disease	0.000597	0.00287	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—IFNGR2—Crohn's disease	0.000597	0.00287	CbGpPWpGaD
Leflunomide—Rash—Mesalazine—Crohn's disease	0.000593	0.00104	CcSEcCtD
Leflunomide—PTK2B—BDNF signaling pathway—JAK2—Crohn's disease	0.000593	0.00285	CbGpPWpGaD
Leflunomide—Dermatitis—Mesalazine—Crohn's disease	0.000593	0.00104	CcSEcCtD
Leflunomide—Headache—Mesalazine—Crohn's disease	0.000589	0.00103	CcSEcCtD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—IL18—Crohn's disease	0.000584	0.00281	CbGpPWpGaD
Leflunomide—Vision blurred—Prednisone—Crohn's disease	0.000575	0.00101	CcSEcCtD
Leflunomide—Ill-defined disorder—Prednisone—Crohn's disease	0.000566	0.000991	CcSEcCtD
Leflunomide—Anaemia—Prednisone—Crohn's disease	0.000564	0.000987	CcSEcCtD
Leflunomide—Nausea—Mesalazine—Crohn's disease	0.000559	0.000979	CcSEcCtD
Leflunomide—Angioedema—Prednisone—Crohn's disease	0.000557	0.000976	CcSEcCtD
Leflunomide—Malaise—Prednisone—Crohn's disease	0.00055	0.000963	CcSEcCtD
Leflunomide—Vertigo—Prednisone—Crohn's disease	0.000548	0.00096	CcSEcCtD
Leflunomide—PTK2B—Signaling by Interleukins—STAT3—Crohn's disease	0.000548	0.00264	CbGpPWpGaD
Leflunomide—PTK2B—EGF/EGFR Signaling Pathway—JAK2—Crohn's disease	0.00054	0.0026	CbGpPWpGaD
Leflunomide—Hypertension—Prednisone—Crohn's disease	0.000527	0.000922	CcSEcCtD
Leflunomide—Myalgia—Prednisone—Crohn's disease	0.000519	0.000909	CcSEcCtD
Leflunomide—Arthralgia—Prednisone—Crohn's disease	0.000519	0.000909	CcSEcCtD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—IL2RA—Crohn's disease	0.000518	0.00249	CbGpPWpGaD
Leflunomide—Anxiety—Prednisone—Crohn's disease	0.000517	0.000906	CcSEcCtD
Leflunomide—Unspecified disorder of skin and subcutaneous tissue—Prednisone—Crohn's disease	0.000516	0.000903	CcSEcCtD
Leflunomide—Discomfort—Prednisone—Crohn's disease	0.000513	0.000898	CcSEcCtD
Leflunomide—Anaphylactic shock—Prednisone—Crohn's disease	0.000498	0.000872	CcSEcCtD
Leflunomide—Infection—Prednisone—Crohn's disease	0.000494	0.000866	CcSEcCtD
Leflunomide—Nervous system disorder—Prednisone—Crohn's disease	0.000488	0.000855	CcSEcCtD
Leflunomide—PTK2B—Immune System—CARD9—Crohn's disease	0.000486	0.00234	CbGpPWpGaD
Leflunomide—Tachycardia—Prednisone—Crohn's disease	0.000486	0.000851	CcSEcCtD
Leflunomide—Skin disorder—Prednisone—Crohn's disease	0.000483	0.000847	CcSEcCtD
Leflunomide—Hyperhidrosis—Prednisone—Crohn's disease	0.000481	0.000843	CcSEcCtD
Leflunomide—PTK2B—Signaling Pathways—ACKR2—Crohn's disease	0.000479	0.0023	CbGpPWpGaD
Leflunomide—Anorexia—Prednisone—Crohn's disease	0.000474	0.000831	CcSEcCtD
Leflunomide—PTK2B—Signaling Pathways—MLN—Crohn's disease	0.000454	0.00218	CbGpPWpGaD
Leflunomide—Musculoskeletal discomfort—Prednisone—Crohn's disease	0.000453	0.000794	CcSEcCtD
Leflunomide—Insomnia—Prednisone—Crohn's disease	0.00045	0.000788	CcSEcCtD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—ICAM1—Crohn's disease	0.000449	0.00216	CbGpPWpGaD
Leflunomide—Paraesthesia—Prednisone—Crohn's disease	0.000447	0.000783	CcSEcCtD
Leflunomide—PTK2B—TCR Signaling Pathway—IL6—Crohn's disease	0.000443	0.00213	CbGpPWpGaD
Leflunomide—Dyspepsia—Prednisone—Crohn's disease	0.000438	0.000767	CcSEcCtD
Leflunomide—PTK2B—BDNF signaling pathway—STAT3—Crohn's disease	0.000435	0.00209	CbGpPWpGaD
Leflunomide—Decreased appetite—Prednisone—Crohn's disease	0.000433	0.000758	CcSEcCtD
Leflunomide—Fatigue—Prednisone—Crohn's disease	0.000429	0.000751	CcSEcCtD
Leflunomide—Constipation—Prednisone—Crohn's disease	0.000426	0.000745	CcSEcCtD
Leflunomide—AHR—Circadian rythm related genes—IL6—Crohn's disease	0.000424	0.00204	CbGpPWpGaD
Leflunomide—ABCG2—Transmembrane transport of small molecules—SLC22A4—Crohn's disease	0.000419	0.00201	CbGpPWpGaD
Leflunomide—ABCG2—Transmembrane transport of small molecules—SLC22A5—Crohn's disease	0.000419	0.00201	CbGpPWpGaD
Leflunomide—CYP2C9—Metapathway biotransformation—GPX4—Crohn's disease	0.000417	0.00201	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—TAGAP—Crohn's disease	0.000415	0.002	CbGpPWpGaD
Leflunomide—Feeling abnormal—Prednisone—Crohn's disease	0.00041	0.000718	CcSEcCtD
Leflunomide—Gastrointestinal pain—Prednisone—Crohn's disease	0.000407	0.000713	CcSEcCtD
Leflunomide—PTK2B—EGF/EGFR Signaling Pathway—STAT3—Crohn's disease	0.000396	0.00191	CbGpPWpGaD
Leflunomide—Urticaria—Prednisone—Crohn's disease	0.000395	0.000692	CcSEcCtD
Leflunomide—Abdominal pain—Prednisone—Crohn's disease	0.000393	0.000689	CcSEcCtD
Leflunomide—Body temperature increased—Prednisone—Crohn's disease	0.000393	0.000689	CcSEcCtD
Leflunomide—PTK2B—VEGFA-VEGFR2 Pathway—IL6—Crohn's disease	0.000386	0.00185	CbGpPWpGaD
Leflunomide—PTK2B—Signaling by Interleukins—IL6—Crohn's disease	0.000383	0.00184	CbGpPWpGaD
Leflunomide—Hypersensitivity—Prednisone—Crohn's disease	0.000367	0.000642	CcSEcCtD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—TYK2—Crohn's disease	0.000365	0.00176	CbGpPWpGaD
Leflunomide—PTK2B—Signaling by VEGF—IL6—Crohn's disease	0.000364	0.00175	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—RSPO3—Crohn's disease	0.000363	0.00174	CbGpPWpGaD
Leflunomide—Asthenia—Prednisone—Crohn's disease	0.000357	0.000625	CcSEcCtD
Leflunomide—CYP1A2—Metapathway biotransformation—GPX4—Crohn's disease	0.000356	0.00171	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—NOD1—Crohn's disease	0.000355	0.00171	CbGpPWpGaD
Leflunomide—Pruritus—Prednisone—Crohn's disease	0.000352	0.000617	CcSEcCtD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—JAK2—Crohn's disease	0.000348	0.00168	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—SEL1L—Crohn's disease	0.000344	0.00165	CbGpPWpGaD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—IFNG—Crohn's disease	0.000342	0.00164	CbGpPWpGaD
Leflunomide—Diarrhoea—Prednisone—Crohn's disease	0.000341	0.000596	CcSEcCtD
Leflunomide—Dizziness—Prednisone—Crohn's disease	0.000329	0.000576	CcSEcCtD
Leflunomide—PTK2B—Immune System—CCR6—Crohn's disease	0.000322	0.00155	CbGpPWpGaD
Leflunomide—Vomiting—Prednisone—Crohn's disease	0.000316	0.000554	CcSEcCtD
Leflunomide—PTK2B—Signaling Pathways—CCR9—Crohn's disease	0.000314	0.00151	CbGpPWpGaD
Leflunomide—Rash—Prednisone—Crohn's disease	0.000314	0.00055	CcSEcCtD
Leflunomide—Dermatitis—Prednisone—Crohn's disease	0.000314	0.000549	CcSEcCtD
Leflunomide—Headache—Prednisone—Crohn's disease	0.000312	0.000546	CcSEcCtD
Leflunomide—CYP2C9—Arachidonic acid metabolism—PTGS2—Crohn's disease	0.000305	0.00147	CbGpPWpGaD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—IL1B—Crohn's disease	0.000305	0.00147	CbGpPWpGaD
Leflunomide—Nausea—Prednisone—Crohn's disease	0.000296	0.000518	CcSEcCtD
Leflunomide—ABCG2—Transmembrane transport of small molecules—GCKR—Crohn's disease	0.000295	0.00142	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—PTPN2—Crohn's disease	0.000295	0.00142	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—GPR65—Crohn's disease	0.000292	0.00141	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—RBX1—Crohn's disease	0.000291	0.0014	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—Crohn's disease	0.000291	0.0014	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—Crohn's disease	0.000279	0.00134	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—ALB—Crohn's disease	0.000272	0.00131	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—PLA2G4F—Crohn's disease	0.000262	0.00126	CbGpPWpGaD
Leflunomide—CYP1A2—Arachidonic acid metabolism—PTGS2—Crohn's disease	0.000261	0.00126	CbGpPWpGaD
Leflunomide—ABCG2—Transmembrane transport of small molecules—SLC11A1—Crohn's disease	0.000261	0.00125	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL1B—Crohn's disease	0.00026	0.00125	CbGpPWpGaD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—STAT3—Crohn's disease	0.000256	0.00123	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—UBE2D1—Crohn's disease	0.000256	0.00123	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—RIPK2—Crohn's disease	0.000248	0.00119	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—ITGA4—Crohn's disease	0.000248	0.00119	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—IL3—Crohn's disease	0.000242	0.00116	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—PTGS2—Crohn's disease	0.000238	0.00114	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—RASGRP1—Crohn's disease	0.000234	0.00112	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—CD79A—Crohn's disease	0.000233	0.00112	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—PLA2G4F—Crohn's disease	0.000231	0.00111	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—TAB1—Crohn's disease	0.000229	0.0011	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—NOD2—Crohn's disease	0.000225	0.00108	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—PLA2G4F—Crohn's disease	0.000224	0.00108	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—MTMR3—Crohn's disease	0.000222	0.00107	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—SOCS1—Crohn's disease	0.000212	0.00102	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—CCR6—Crohn's disease	0.000208	0.001	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—MTMR3—Crohn's disease	0.000196	0.000944	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—IL18—Crohn's disease	0.000191	0.000917	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—MTMR3—Crohn's disease	0.00019	0.000915	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—RBX1—Crohn's disease	0.000188	0.000906	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—Crohn's disease	0.000188	0.000906	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—TNF—Crohn's disease	0.000188	0.000906	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—PTGER4—Crohn's disease	0.000183	0.000882	CbGpPWpGaD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—IL6—Crohn's disease	0.000179	0.000859	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—FADS1—Crohn's disease	0.000173	0.000834	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—IL2RA—Crohn's disease	0.000169	0.000814	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—UBE2D1—Crohn's disease	0.000165	0.000795	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—GPX4—Crohn's disease	0.000162	0.000781	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—RIPK2—Crohn's disease	0.00016	0.000771	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—CRP—Crohn's disease	0.00016	0.000768	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—IL3—Crohn's disease	0.000156	0.000752	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—TLR4—Crohn's disease	0.000153	0.000736	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—FADS1—Crohn's disease	0.000153	0.000735	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—RASGRP1—Crohn's disease	0.000151	0.000727	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—FADS1—Crohn's disease	0.000148	0.000713	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—ICAM1—Crohn's disease	0.000147	0.000706	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—GPX4—Crohn's disease	0.000143	0.000688	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—GPX4—Crohn's disease	0.000139	0.000667	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—GCKR—Crohn's disease	0.000138	0.000665	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—SOCS1—Crohn's disease	0.000137	0.000659	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—TYK2—Crohn's disease	0.000119	0.000574	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—SMAD3—Crohn's disease	0.000118	0.000569	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—PLA2G4F—Crohn's disease	0.000117	0.000561	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—JAK2—Crohn's disease	0.000114	0.000547	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—IFNG—Crohn's disease	0.000112	0.000537	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—IL2RA—Crohn's disease	0.000109	0.000526	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—CD4—Crohn's disease	0.000108	0.000519	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—IL1B—Crohn's disease	9.96e-05	0.000479	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—PLA2G4F—Crohn's disease	9.96e-05	0.000479	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—MTMR3—Crohn's disease	9.91e-05	0.000477	CbGpPWpGaD
Leflunomide—ABCG2—Transmembrane transport of small molecules—ALB—Crohn's disease	9.39e-05	0.000452	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—MTMR3—Crohn's disease	8.47e-05	0.000407	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—STAT3—Crohn's disease	8.35e-05	0.000402	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—FADS1—Crohn's disease	7.72e-05	0.000371	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—TYK2—Crohn's disease	7.71e-05	0.000371	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—JAK2—Crohn's disease	7.36e-05	0.000354	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—GPX4—Crohn's disease	7.23e-05	0.000348	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—GCKR—Crohn's disease	6.98e-05	0.000336	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—CXCL8—Crohn's disease	6.71e-05	0.000323	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—FADS1—Crohn's disease	6.6e-05	0.000317	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—GPX4—Crohn's disease	6.18e-05	0.000297	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—GCKR—Crohn's disease	5.97e-05	0.000287	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—IL6—Crohn's disease	5.83e-05	0.000281	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—STAT3—Crohn's disease	5.4e-05	0.00026	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—ALB—Crohn's disease	4.99e-05	0.00024	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—ALB—Crohn's disease	4.4e-05	0.000212	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—Crohn's disease	4.36e-05	0.00021	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—ALB—Crohn's disease	4.26e-05	0.000205	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—PTGS2—Crohn's disease	3.85e-05	0.000185	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—IL6—Crohn's disease	3.77e-05	0.000181	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—Crohn's disease	3.73e-05	0.000179	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—ALB—Crohn's disease	2.22e-05	0.000107	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—PTGS2—Crohn's disease	1.94e-05	9.35e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—ALB—Crohn's disease	1.9e-05	9.13e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—PTGS2—Crohn's disease	1.66e-05	7.99e-05	CbGpPWpGaD
